- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05936632
Wait Time Preferences of the US Public for New Drugs: a Discrete Choice Experiment
Wait Time Preferences of the US Public for New Drugs With Uncertain Treatment Benefits: a Discrete Choice Experiment
To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.
It is not currently known if (and under which circumstances) the public would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.
This study aims to elicit the preferences of the US public for wait times and clinical uncertainty of new drugs.
To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, WC2A 2AE
- London School of Economics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Individuals previously or currently diagnosed with any type of cancer.
- Individuals with immediate family members previously or currently diagnosed with any type of cancer.
Exclusion Criteria:
- Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preferences for treatment attributes and trade-offs between attributes.
Time Frame: Through study completion, an average of 4-8 weeks.
|
Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire.
Preferences are measured on relative utility scale (arbitrary units, no min/max).
Utility indicates preference e.g., higher values are more preferred (better).
|
Through study completion, an average of 4-8 weeks.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 213621
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Discrete Choice Experiment (DCE)
-
King's College LondonRecruitingSurgery | Patient Satisfaction | Patient Preference | Muscle Invasive Bladder Cancer | Sexual WellbeingUnited Kingdom
-
LinkCare GmbHGrünenthal GmbH; Schmerzpraxis Wiesbaden; Schmerz- und Palliativzentrum Rhein-Main...CompletedNeuropathic Pain | Patient Preference | Neuralgia PeripheralGermany
-
Johns Hopkins Bloomberg School of Public HealthPatient-Centered Outcomes Research InstituteUnknownType II DiabetesUnited States
-
Imperial College LondonUniversity of AberdeenCompletedQuality of Life | Surgery | Patient Satisfaction | Health Care Utilization | Prostate Cancer Metastatic | Radiotherapy Side Effect | Urologic CancerUnited Kingdom
-
Leiden University Medical CenterRecruitingUveal MelanomaNetherlands
-
UNC Lineberger Comprehensive Cancer CenterFogarty International Center of the National Institute of HealthCompletedCervical CancerSouth Africa
-
University of North Carolina, Chapel HillCompletedColorectal Cancer | Prostate Cancer | Colon CancerUnited States